CHRS vs REGN: Which Stock is Better?

Side-by-side comparison of Coherus Oncology Inc and Regeneron Pharmaceuticals Inc in 2026

Comparison Updated:

CHRS

Coherus Oncology Inc

$1.99

REGN

Regeneron Pharmaceuticals Inc

$749.41

Key Metrics Comparison

MetricCHRSREGNWinner
Market Cap$296.78M$79.35BREGN
P/E RatioN/A18.08REGN
EPS (TTM)$N/A$41.51REGN
Revenue Growth0.6%0.0%CHRS
Gross Margin67.2%44.6%CHRS

Analyze CHRS

Full quant analysis

Analyze REGN

Full quant analysis

Analyze Each Stock

Frequently Asked Questions

Is CHRS or REGN a better investment?

Comparing CHRS and REGN: Coherus Oncology Inc has a market cap of $296.78M while Regeneron Pharmaceuticals Inc has $79.35B. Both companies have their strengths - use our detailed metrics comparison to make an informed decision.

What is the difference between CHRS and REGN?

CHRS (Coherus Oncology Inc) and REGN (Regeneron Pharmaceuticals Inc) differ in valuation, growth rates, and profitability metrics. Our comparison shows which company leads in each category.

Which stock has better value: CHRS or REGN?

Based on P/E ratios, compare detailed valuation metrics on our dashboard.

Which is growing faster: CHRS or REGN?

CHRS has higher revenue growth at 0.6% vs 0.0% for REGN.

Which company is more profitable: CHRS or REGN?

Coherus Oncology Inc (CHRS) has higher gross margins at 67.2% compared to 44.6% for REGN.

Which is the larger company: CHRS or REGN?

Regeneron Pharmaceuticals Inc (REGN) is larger with a market cap of $79.35B compared to $296.78M for CHRS.

Should I buy CHRS or REGN in 2026?

Both CHRS and REGN have investment merit. CHRS trades at $1.99 while REGN trades at $749.41. Consider your investment goals, risk tolerance, and portfolio diversification before deciding. Our AI analysis tools can provide personalized insights.

What are the key differences between CHRS and REGN stock?

Key differences: Market Cap ($296.78M vs $79.35B), P/E Ratio (N/A vs 18.1x), Revenue Growth (0.6% vs 0.0%), Gross Margin (67.2% vs 44.6%).

Popular Stock Comparisons